Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
Takaaki Oba, Mark D. Long, Tibor Keler, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 115

Showing 1-25 of 115 citing articles:

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 299
The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis
Feng Li, Caichen Li, Xiuyu Cai, et al.
EClinicalMedicine (2021) Vol. 41, pp. 101134-101134
Open Access | Times Cited: 252
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 131
Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses
Joyce Wei, Welby Montalvo-Ortiz, Lola Yu, et al.
Science Immunology (2021) Vol. 6, Iss. 58
Open Access | Times Cited: 111
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Ignacio Heras‐Murillo, Irene Adán‐Barrientos, Miguel Á. Galán, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 257-277
Closed Access | Times Cited: 105
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Yi Wang, Kai Conrad Cecil Johnson, Margaret E. Gatti‐Mays, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 93
NSUN2 is a glucose sensor suppressing cGAS/STING to maintain tumorigenesis and immunotherapy resistance
Tingjin Chen, Zhigang Xu, Luo Jie, et al.
Cell Metabolism (2023) Vol. 35, Iss. 10, pp. 1782-1798.e8
Closed Access | Times Cited: 80
Targeting innate immune pathways for cancer immunotherapy
Longyue L. Cao, Jonathan C. Kagan
Immunity (2023) Vol. 56, Iss. 10, pp. 2206-2217
Open Access | Times Cited: 78
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Adil Parvez, Furqan Choudhary, Priyal Mudgal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 67
Cross-priming in cancer immunology and immunotherapy
Carlos Luri‐Rey, Álvaro Teijeira, Stefanie K. Wculek, et al.
Nature reviews. Cancer (2025)
Closed Access | Times Cited: 3
Tumor‐Associated Macrophages Nano‐Reprogrammers Induce “Gear Effect” to Empower Glioblastoma Immunotherapy
Yang Wang, Guangzhe Li, Jianlong Su, et al.
Small (2025)
Closed Access | Times Cited: 2
FBXO31-mediated ubiquitination of OGT maintains O-GlcNAcylation homeostasis to restrain endometrial malignancy
Na Zhang, Yang Meng, Song Mao, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Dendritic cell maturation in cancer
Chang Moon, Meriem Belabed, Matthew D. Park, et al.
Nature reviews. Cancer (2025)
Closed Access | Times Cited: 2
Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy
Marie Siwicki, Nicolas A. Gort-Freitas, Marius Messemaker, et al.
Science Immunology (2021) Vol. 6, Iss. 61
Open Access | Times Cited: 63
Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy
Junmeng Zhu, Yaohua Ke, Qin Liu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 52
Control of Dendritic Cell Function Within the Tumour Microenvironment
Yukti Hari Gupta, Abida Khanom, Sophie E. Acton
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 46
Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy
Elnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113906-113906
Open Access | Times Cited: 46
Innate PD-L1 limits T cell–mediated adipose tissue inflammation and ameliorates diet-induced obesity
Christian Schwartz, Viviane Schmidt, Andrea Deinzer, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 635
Open Access | Times Cited: 38
The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy
Keywan Mortezaee, Jamal Majidpoor, Ebrahim Kharazinejad
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114646-114646
Open Access | Times Cited: 26
Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors
Lucía López, Luciano Gastón Morosi, Federica La Terza, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors
Anthony W. Tolcher, Joshua Brody, Nishanthan Rajakumaraswamy, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 14, pp. 2954-2963
Open Access | Times Cited: 9
Comprehensive pan-cancer analysis of YBX family reveals YBX2 as a potential biomarker in liver cancer
Ze Yuan, Binbin Li, Wenmin Liao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Dendritic cell subsets and implications for cancer immunotherapy
Michael Y. Chen, Felicia Zhang, S. Peter Goedegebuure, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy
Yu Zhao, Yuejiao Cao, Yiqi Chen, et al.
Immunology (2021) Vol. 164, Iss. 3, pp. 507-523
Open Access | Times Cited: 45
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
Jannie Borst, Julia Busselaar, Douwe M. T. Bosma, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 8, pp. 1911-1920
Open Access | Times Cited: 43
Page 1 - Next Page

Scroll to top